Loaded of Etodolac on Zinc Oxide Nanoparticles

Abstract

Etodolac, a chiral nonsteroidal anti-inflammatory drug (NSAID), is widely used for pain management and arthritis treatment. However, it suffers from various side effects, including gastrotoxicity and cardiovascular risks. This study investigated the potential of zinc oxide nanoparticles (ZnO NPs) as a delivery platform for etodolac to improve its efficacy and mitigate these adverse effects. ZnO NPs possess several attractive properties for drug delivery applications, including low toxicity, biodegradability, and the ability to target specific tissues. In this study, etodolac was successfully loaded onto ZnO NPs, and the resulting nanocomposites were characterized using Fourier-transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM). FT-IR analysis confirmed the successful loading of etodolac onto the ZnO NPs. Additionally, SEM images revealed morphological changes on the surface of the nanocomposites compared to pure ZnO NPs, further indicating successful drug loading. These findings demonstrate the feasibility of developing etodolac-loaded ZnO NPs as a promising approach for targeted drug delivery. Further studies are warranted to investigate the vivo efficacy and safety of these nanocomposites, paving the way for their potential clinical application.